# Lubris Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lubris-biopharma

- Industry: Biotechnology
- Headquarters: Weston, US
- Website: www.lubris.net
- Latest round: Series A (Jul 1, 2013)
- Investors on record: 2

## About

Lubris Biopharma, LLC focuses on developing recombinant human lubricin, a biopharmaceutical product designed to address conditions such as dry eye disease and osteoarthritis, improving patient outcomes through targeted therapies.Lubris Biopharma, LLC was founded in 2009 in Weston, US. The company specializes in biopharmaceuticals and was established by a team including Benjamin Sullivan, Edmund Pitcher, Edward Truitt, and Harry Barnett. Edward Truitt currently serves as the CEO. The company has been involved in one deal, raising SERIES A funding in July 2013.Lubris Biopharma specializes in the development of recombinant human lubricin, a biopharmaceutical product aimed at addressing dry eye disease, osteoarthritis, and various age- and inflammation-related conditions. Lubricin functions as a biological lubricant, protecting tissues from friction-related damage throughout the body. The company collaborates with major pharmaceutical firms for broader distribution of its products, which primarily serve patients suffering from dry eye and osteoarthritis in markets like North America, Europe, and parts of Asia.Lubris Biopharma operates on a revenue generation model centered around partnerships and licensing agreements with larger pharmaceutical companies. This includes licensing its recombinant human lubricin technology, allowing partners to handle commercialization. While specific pricing details are not disclosed, the company’s pricing strategy reflects the value of its patented technologies and their benefits in clinical applications.Lubris Biopharma aims to develop and launch new products targeting dry eye disease and osteoarthritis, with specific release dates to be announced in the future. The company plans to expand its market presence into new geographic regions, particularly in Europe and Asia, by leveraging its recent SERIES A funding raised in July 2013 from Thynk Capital and Tarnagulla Ventures, though specific allocation details for this funding have not been disclosed.

## Funding rounds

- Series A, Jul 1, 2013 — Tarnagulla Ventures, Thynk Capital

## Investors

- Tarnagulla Ventures (https://capitalatlas.ai/funds/tarnagulla-ventures) — Series A
- Thynk Capital (https://capitalatlas.ai/funds/thynk-capital) — Series A